These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 7684768

  • 1. Clinical significance of serum hepatocyte growth factor levels in liver diseases.
    Hioki O, Watanabe A, Minemura M, Tsuchida T.
    J Med; 1993; 24(1):35-46. PubMed ID: 7684768
    [Abstract] [Full Text] [Related]

  • 2. Weight of resected liver is positively correlated with serum hHGF level.
    Miyata K, Taniguchi H, Takeuchi K, Koyama H, Tanaka H, Takahashi T.
    Hepatogastroenterology; 1996; 43(12):1589-93. PubMed ID: 8975970
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Changes in serum human hepatocyte growth factor levels after transcatheter arterial embolization and partial hepatectomy.
    Kaneko A, Hayashi N, Tanaka Y, Ito T, Kasahara A, Kubo M, Mukuda T, Fusamoto H, Kamada T.
    Am J Gastroenterol; 1992 Aug; 87(8):1014-7. PubMed ID: 1322635
    [Abstract] [Full Text] [Related]

  • 5. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases.
    Yamagamim H, Moriyama M, Matsumura H, Aoki H, Shimizu T, Saito T, Kaneko M, Shioda A, Tanaka N, Arakawa Y.
    Cancer; 2002 Aug 15; 95(4):824-34. PubMed ID: 12209727
    [Abstract] [Full Text] [Related]

  • 6. Serum hepatocyte growth factor levels in liver diseases: clinical implications.
    Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T.
    Hepatology; 1995 Jan 15; 21(1):106-12. PubMed ID: 7806142
    [Abstract] [Full Text] [Related]

  • 7. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
    Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C.
    Cancer; 2002 Dec 15; 95(12):2539-45. PubMed ID: 12467068
    [Abstract] [Full Text] [Related]

  • 8. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma.
    Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A, D'Agostino L.
    Clin Endocrinol (Oxf); 2003 Dec 15; 59(6):699-706. PubMed ID: 14974910
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma.
    Hu RH, Lee PH, Yu SC, Sheu JC, Lai MY.
    Hepatogastroenterology; 1999 Dec 15; 46(27):1842-7. PubMed ID: 10430357
    [Abstract] [Full Text] [Related]

  • 11. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS, Hong SI, Park SY, Son Y, Lee YS, Chung YH, Yang SK, Suh DJ, Min YI.
    Anticancer Res; 1995 Dec 15; 15(6B):2777-80. PubMed ID: 8669863
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, Lee PC, Chi CW, Lui WY, Lee SD.
    Eur J Surg Oncol; 2007 Mar 15; 33(2):208-12. PubMed ID: 17140760
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early detection of hepatoma in cirrhosis by serial quantitation of alpha-1-foetoprotein in serum.
    Niermeijer P, Gips CH, Marrink J, QUE GS.
    Neth J Med; 1976 Mar 15; 19(1):25-8. PubMed ID: 55985
    [No Abstract] [Full Text] [Related]

  • 16. Early detection of hepatoma in cirrhosis by serial quantitation of alpha-1-foetoprotein in serum.
    Niermeijer P, Gips CH, Marrink J, Qué GS.
    Neth J Med; 1976 Mar 15; 19(1):15-8. PubMed ID: 55984
    [No Abstract] [Full Text] [Related]

  • 17. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.
    Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, Cheng JS, Huang JS, Ger LP, Huang SM, Yen MY, Yang YF.
    Anticancer Res; 1997 Mar 15; 17(4A):2803-9. PubMed ID: 9252719
    [Abstract] [Full Text] [Related]

  • 18. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma.
    Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y.
    J Gastroenterol; 2004 Dec 15; 39(12):1182-8. PubMed ID: 15622483
    [Abstract] [Full Text] [Related]

  • 19. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K, Aoyagi Y.
    Hepatogastroenterology; 1998 Dec 15; 45(23):1737-41. PubMed ID: 9840138
    [Abstract] [Full Text] [Related]

  • 20. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.
    Xu J, Shi J, Wang YP, Lin Y, Chen YX, Lu J, Zeng X, Xie WF.
    Med Sci Monit; 2009 Jun 15; 15(6):CR274-9. PubMed ID: 19478697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.